Tech Company Financing Transactions

Second Genome Funding Round

Second Genome closed a $42.6 million Series B venture capital round on 4/20/2016. Investors included Pfizer Venture Investments, Roche Venture Fund and Advanced Technology Ventures.

Transaction Overview

Company Name
Second Genome
Announced On
4/20/2016
Transaction Type
Venture Equity
Amount
$42,600,000
Round
Series B
Investors

Pfizer Venture Investments (Lead Investor) (Elaine James)

Roche Venture Fund (Lead Investor) (Carole Nuechterlein)

Advanced Technology Ventures (Michael Carusi)

Adveq

Digitalis Ventures

private investors (Matthew Winkler)

Lifeforce Ventures

Mayo Medical Ventures

MBL Venture Capital

Morgenthaler Ventures (Jason Lettmann)

Seraph Group

Proceeds Purpose
The funds will be used to further expand the Second Genome Microbiome Discovery Platform in a range of indications associated with barrier function, insulin sensitivity, and immune regulation. In addition, proceeds from the financing will be used to advance the clinical investigation of SGM-1019, a small molecule inhibitor of a key microbiome-mediated target to address inflammation and pain in ulcerative colitis, through human proof-of-concept studies.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
341 Allerton Ave.
South San Francisco, CA 94080
USA
Phone
(650) 440-4606
Website
www.secondgenome.com
Email Address
[email protected]
Overview
Founded in 2009 by leading experts in microbial research, molecular diagnostics, and biotechnology R&D, Second Genome is using its proprietary Microbiome Signature Discovery platform to generate novel insights relating the microbiome with a wide range of human health disorders.
Profile
Second Genome LinkedIn Company Profile
Social Media
Second Genome Company Twitter Account
Company News
Second Genome News
Facebook
Second Genome on Facebook
YouTube
Second Genome on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Glenn Nedwin
  Glenn Nedwin LinkedIn Profile  Glenn Nedwin Twitter Account  Glenn Nedwin News  Glenn Nedwin on Facebook
Chief Medical Officer
Matthew McClure
  Matthew McClure LinkedIn Profile  Matthew McClure Twitter Account  Matthew McClure News  Matthew McClure on Facebook
Chief Scientific Officer
Karim Dabbagh
  Karim Dabbagh LinkedIn Profile  Karim Dabbagh Twitter Account  Karim Dabbagh News  Karim Dabbagh on Facebook
Vice President
Todd DeSantis
  Todd DeSantis LinkedIn Profile  Todd DeSantis Twitter Account  Todd DeSantis News  Todd DeSantis on Facebook
VP - Bus. Development
Anu Hoey
  Anu Hoey LinkedIn Profile  Anu Hoey Twitter Account  Anu Hoey News  Anu Hoey on Facebook
VP - Finance
Brian Dowd
  Brian Dowd LinkedIn Profile  Brian Dowd Twitter Account  Brian Dowd News  Brian Dowd on Facebook
VP - Human Resources
James Sjoerdsma
  James Sjoerdsma LinkedIn Profile  James Sjoerdsma Twitter Account  James Sjoerdsma News  James Sjoerdsma on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/20/2016: PicsArt venture capital transaction
Next: 4/20/2016: Brighter venture capital transaction

 

Share this article

 

News on VC Transactions

We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.